Jump to content
SurvivingAntidepressants.org will be closed to new registrations November 1st through December 31, 2023 ×

Brown & Lewis, 2020. The Patient Voice: Antidepressant withdrawal, MUS and FND


Recommended Posts



This article is free to access at the above URL. As the article is short, the whole text is also included here


This article is an opinion piece in the British Journal of General Practice (read by thousands of Drs). It discusses the issues around the misdiagnosis of symtoms caused by antidepressant side effects and withdrawal as Medically Unexplained Symptoms (MUS) or Functional Neurological Disorders (FND). This is a huge problem amongst those impacted.


It referes to the patient voice paper here:


The Patient Voice: Antidepressant withdrawal, MUS and FND

Posted by BJGP Life | 3 Dec 2020 | Opinion | 2


Marion Brown (left) is a retired psychotherapist and researcher/campaigner/Petitioner on behalf of the patient self-help peer group Recovery and renewal. Scottish petition: Prescribed drug dependence and withdrawal, see Twitter: @recover2renew and http://www.parliament.scot/GettingInvolved/Petitions/PE01651

Stevie Lewis (right) is an expert patient and researcher/campaigner for recognition and for support services. Petitioner: Welsh Petition: Prescribed drug dependence and withdrawal, see https://business.senedd.wales/mgIssueHistoryHome.aspx?IId=19952


We write as petitioners respectively for Scottish and Welsh Public Parliamentary Petitions, launched 2017, to express our ongoing concerns about mis-diagnosis particularly of antidepressant dependence and withdrawal. It is now accepted that antidepressants, especially SSRIs and SNRIs, affect the central nervous system, may be dependence-forming and may cause side effects, adverse reactions and withdrawal (Public Health England 2019 Dependence and withdrawal associated with some prescribed medicines: an evidence review (publishing.service.gov.uk).


In 2019 the Royal College of Psychiatrists (RCPsych) released a position statement on antidepressants.1 In September 2020 they published a leaflet on ‘stopping antidepressants’, endorsed by the Royal College of General Practitioners (RCGP), the Royal College of Pharmacists and NICE.2

Our recently published research paper “The ‘patient voice’: patients who experience antidepressant withdrawal symptoms are often dismissed, or misdiagnosed with relapse, or a new medical condition”, written together with Anne Guy and Mark Horowitz, collates patient evidence published for our petitions and was commissioned by the All Party Parliamentary Group for Prescribed Drug Dependence.3 This paper tracks 158 collated patient accounts of the aetiology of the development of all manner of prescribed drug-related ‘symptoms’ which have been variously mis-diagnosed as ‘relapse’, other illnesses, ‘unexplained symptoms’ and/or ‘functional’ disorders.  The paper highlights eight ‘failure points’ where the system has led to exacerbation of the problems, for patients and prescribers.

Prescribed drug-related symptoms … have been variously mis-diagnosed.


We are alarmed to see the recent BMJ ‘Practice Pointer’ by Stone et al encouraging GPs to ‘recognise and understand’ Functional Neurological Disorder (FND).4   We have responded to this BMJ article (rapid responses (4)) – as has Jill Nickens, co-founder of Akathisia Alliance for Education and Research Akathisia Alliance for Education and Research.  Our ongoing concerns are that GPs are being further guided to mis-diagnose and overlook the vitally important indications of serious prescribed drug effects, including life-threatening akathisia, and that this is leading to avoidable harm, chronic illness, disability and deaths.  The following essential questions (for practitioners and patients) do not feature in the list of questions suggested by Stone et al:4

  • What is the person’s medication history – from the very first prescribed medications, and then over the long term?
  • When did the ‘unexplained’/ ‘functional’ symptoms first become apparent, especially in relation to prescribed medications, i.e. the possibility of adverse medication effects or withdrawal?

Our own research shows that “In this sample [of 158 cases] 25% of patients with antidepressant withdrawal presenting to their GP were diagnosed with MUS [medically unexplained symptoms], a ‘functional neurological disorder’ [FND] or ‘chronic fatigue syndrome’. Many of the signs and symptoms associated with these medically unexplained disorders, captured in the often used PHQ-15, overlap with the symptoms of antidepressant withdrawal, including insomnia, feeling tired, nausea, indigestion, racing heart, dizziness, headaches and back pain”.3

Many of the signs and symptoms associated with … medically unexplained disorders, …. overlap with the symptoms of antidepressant withdrawal.


The RCGP ‘Top Ten Tips’ for GPs states: “Number 3. MUS account for up to 20% of GP consultations. 25% persist in primary care for over 12 months”. The RCPsych estimate “About I in 4 people who see their GP have such symptoms” and “In a neurological outpatient setting, it is 1 in 3 patients or more”…“Another common term is ‘functional’ – the symptoms are due to a problem in the way the body is functioning, even though the structure of the body is normal”.5

We urge GPs to read our ‘Patient Voice’ paper, to refer to the new information about ‘stopping antidepressants’, and for the RCGP to urgently provide updated guidance for all prescribers reflecting this published and emerging evidence.2,3

One author’s (Stevie Lewis) BJGP article ‘Guidance for psychological therapists: information for GPs advising patients on antidepressant withdrawal’ is relevant.6  Patients will increasingly be asking their prescribers to support their need for informed autonomy to manage and reduce their antidepressant burden so as to minimise further harm.

Most urgently, we urge individual prescribers to always raise with their patients possibilities such as antidepressant adverse effects and/or potential dose-change and withdrawal issues before initially prescribing an antidepressant for any patient – and before attributing patients’ subsequent development of ‘unexplained’ ‘functional’ symptoms to psychosomatic ‘medically unexplained’ or ‘functional’ syndromes and disorders.  This is vital to the all-important doctor/patient relationship, to properly informed consent – and to reduce prescribed drug damage and resulting nervous system chaos.


1. RCPsych.  (2019) Position Statement Antidepressants and Depression   ps04_19—antidepressants-and-depression.pdf (rcpsych.ac.uk)

2.  NICE – Ref CG90  Endorsed resource – Stopping antidepressants | Depression in adults: recognition and management | Guidance | NICE

3. Guy A, Brown M, Lewis S, Horowitz M. (2020) The Patient Voice… antidepressant withdrawal .  Sage Therapeutic Advances in Psychopharmacology https://journals.sagepub.com/doi/10.1177/2045125320967183

4. Stone J, Burton C, Carson A. (2020) Recognising and explaining functional neurological disorder. BMJ  https://doi.org/10.1136/bmj.m3745

5. Royal College of Psychiatrists – Medically unexplained symptoms  Medically unexplained symptoms | Royal College of Psychiatrists (rcpsych.ac.uk)

6. Lewis S. (2020) Guidance for Psychological Therapists. Br J Gen Pract  https://doi.org/10.3399/bjgp20X709685


2011 - started Venlafaxine (again) at 75mg Raised to 150 mg at some point - unsure of dates. Reduced back down to 75 mg. Doctor advised this would be a lifetime, maintenance dose

2017 - Side effects now intolerable. Started taper from June 15th - 5% dose reduction steps (two 12 hourly doses).

2017 - October 20th - took last dose of Venlafaxine - 4 mg. Debilitating symptoms followed.

2017/18 - diazepam - 8mg/day for 1 month - 7 week taper Feb 2018

2017/18 - duloxetine - max 90mg - now stopped

2018 - Feb 25mg quetiapine, increased to 50mg.

2018 - March/April - increased venlafaxine slowly (10mg steps) to 75 mg/day. Recovery from withdrawal followed.

2018 - July 13 - stopped quetiapine after 2 month taper. Late July - had to reinstate quetiapine due to intolerable withdrawal. Now tapering from 25mg

2019 - June - stopped quetiapine after 10 month taper. Mild insomnia only symptom.

2021 - June - venlafaxine approx 6.0 mg see Taper history details

Link to comment
Share on other sites

  • Create New...

Important Information

Terms of Use Privacy Policy